Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic HER2-mutated NSCLC By Ogkologos - November 14, 2025 35 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SOHO-01 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR How My Inherited Cancer Diagnosis Has Made Me a Better Oncologist February 23, 2021 What to Do When You Are Diagnosed With Cancer During Pregnancy January 19, 2021 Neoadjuvant Pertuzumab/Trastuzumab Demonstrates Long-Term Cardiac Safety in HER2-Positive Breast Cancer May 7, 2021 EMA Recommends Granting a Marketing Authorisation for Tislelizumab August 4, 2023 Load more HOT NEWS Repurposing radiotherapy drugs could give immunotherapy a boost Beloved Kindergarten Teacher Who Inspired Her Community Dies of Breast Cancer... Occurrence of Interstitial Lung Disease Related to Trastuzumab Deruxtecan in Patients... Study Tests Immunotherapy in People with Cancer and Autoimmune Diseases
